GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes

Regulatory Peptides

Volumn 167, Issue 2-3, 2011, Pages 177-184

  Tomas, Eva ^a   Stanojevic, Violeta ^a   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diabetes; Insulin resistance; Liver; Metabolic syndrome; NEP 24.11

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [28-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; PROTEIN NEP 24.11; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; GLUCONEOGENESIS; HORMONE ACTION; LIVER CELL; MALE; METABOLIC INHIBITION; MITOCHONDRION; MOUSE; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEPATOCYTES; MICE; MICE, INBRED C57BL; MICE, OBESE; MITOCHONDRIA; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON;

MUS;

EID: 79953173175     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.01.003     Document Type: Article

References (36)

1. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
2. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20:876-913.
3. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
4. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
5. Sonne D.P., Engstrøm T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249.
6. Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
7. Ban K., Kim K.H., Cho C.K., Sauvé M., Diamandis E.P., Backx P.H., Drucker D.J., Husain M. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
8. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478:136-142.
9. Elahi D., Egan J.M., Shannon R.P., Meneilly G.S., Khatri A., Habener J.F., Andersen D.K. Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity 2008, 16:1501-1509.
10. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94:1843-1852.
11. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010, 21:59-67.
12. Tomas E., Stanojevic V., Habener J.F. GLP-1(9-36)amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 2010, 42:657-662.
13. Meier J.J., Gethmann A., Nauck M.A., Gotze O., Schmitz F., Deacon C.F., Gallwitz B., Schmidt W.E., Holst J.J. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006, 290:E1118-E1123.
14. Tomas E., Wood J.A., Habener J.F. GLP-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diab Obes Metab 2011, 13:26-33.
15. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., Göke R., Göke B., Thole H., Zimmermann B., Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995, 58:149-156.
16. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004, 36:761-765.
17. Plamboeck A., Holst J.J., Carr R.D., Deacon C.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005, 48:1882-1890.
18. Brownlee M. GLP-1 (9-36) methods and compositions. USPTO application number: US 2008/-194483 A1 Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=15&f=G&l=50&co1=AND&d=PG01&s1=brownlee.IN.&OS=IN/brownlee&RS=IN/brownlee. http://appft1.uspto.gov/netahtml/PTO/search-bool.html.
19. Hirst J. Towards the molecular mechanism of respiratory complex I. Biochem J 2009, 425:327-339.
20. Liu H.Y., Collins Q.F., Xiong Y., Moukdar F., Lupo E.G., Liu Z., Cao W. Prolonged treatment of primary hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase. J Biol Chem May 11 2007, 282:14205-14212.
21. Haas J.T., Biddinger S.B. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009, 20:206-210.
22. Grattagliano I., Palmieri V.O., Portincasa P., Moschetta A., Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008, 19:491-504.
23. Ott M., Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
24. Zhao K., Zhao G.M., Wu D., Soong Y., Birk A.V., Schiller P.W., Szeto H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2007, 279:34682-34690.
25. Simonsen L., Pilgaard S., Carr R.D., Kanstrup A.B., Holst J.J., Deacon C.F. Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats. Horm Metab Res 2009, 41:851-853.
26. Flock G., Baggio L.L., Longuet C., Drucker J.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007, 56:3006-3013.
27. Szeto H.H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 2006, 8:E277-E283.
28. Brun C., Philip-Couderc P., Raggenbass M., Roatti A., Baertschi A.J. Intracellular targeting of truncated secretory peptides in the mammalian heart and brain. FASEB J 2006, 20:732-734.
29. Yamada H., Chounan R., Higashi Y., Kurihara N., Kido H. Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBS Lett 2004, 578:331-336.
30. Lemire B.D., Frankenhauser C., Baker A., Schatz Z. The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity. J Biol Chem 1989, 264:20205-20215.
31. Chatre L., Matheson L.A., Jack A.S., Hanton S.L., Brandizzi F. Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants. J Exp Bot 2009, 60:741-749.
32. Baldwin G.S. Antiproliferative gastrin/cholecystokinin receptor antagonists target the 78-kDa gastrin-binding protein. Proc Natl Acad Sci USA 1994, 91:7593-7597.
33. Hashimoto T., Shindo Y., Souri M., Baldwin G.S. A new inhibitor of mitochondrial fatty acid oxidation. J Biochem 1996, 119:1196-1201.
34. Rodrigue-Way A., Demers A., Ong H., Tremblay A. A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes. Endocrinology 2007, 148:1009-1018.
35. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35years. Diab Metab Rev 1998, 14:263-283.
36. Stein L.L., Dong M.H., Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009, 26:893-907.